

#12

Docket No. ORT-1238

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AndHB

Applicants : Zhang et al.
Serial No. : 09/603,338
Filed : June 26, 2000
Title : NOVEL INDAZOLE PEPTIDOMIMETICS AS
THROMBIN RECEPTOR ANTAGONISTS
Art Unit : 1653
Examiner : A.A. Mohamed

RECEIVED

OCT 16 2002

TECH CENTER 1600/2900

Honorable Commissioner of Patents
Washington, D.C. 20231

AMENDMENT

Dear Sir:

In response to the Office Action of August 22, 2002,
Notice to Comply with Sequence Rules, please amend the above-
identified application as follows:

In the Specification:

Please replace the paragraph beginning on page 31, line 11, with
the following rewritten paragraph:

CHRF membranes (Jones, *Biochim. Biophys. Acta* **1992**, 1136, 272)
are thawed from -70°C, centrifuged at maximum speed for 5 min,
washed twice with binding buffer (50 mM HEPES containing 5 mM
MgCl₂ and 0.1% BSA), and re-suspended in binding buffer (25
µg/100 mL). 100 µL of membranes are added to the 24-Wallac
plates and delivered to the Tomtech apparatus. In a typical
experiment, 6 µL of samples (from a 125 µg/mL intermediary
plate, 20% DMSO) and 44 µL buffer are delivered to the plates
(final conc. of compounds is 3.7 µg/mL, 0.6% DMSO).
Similarly, 6 µL 20% DMSO and 44 µL buffer are delivered to
both column 1 (NSB) and column 12 (TB). 10 µL Ser-pFPhe-Har-
Leu-Har-Lys-Tyr-NH₂ SEQ. ID. No. 2 (721-40; 500 µM in
deionized water) is added to column 1. 50 µL tritiated 721-40